title: Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies.
abstract: Nineteen patients with refractory solid malignancies received individualized combinations of mitomycin C conjugated murine monoclonal antibodies selected by immunohistochemical and flow cytometric screening of tumor specimens. There were no responses in this Phase I study. Thrombocytopenia precluded escalation above a mitomycin C dose of 60 mg per treatment cycle. Preclinical, clinical, and toxicity experiences with this investigational approach to the treatment of cancer are discussed.
authors.affiliation: Williamson Medical Center, Franklin, TN.
authors.forename: D
authors.initials: D
authors.lastname: Orr
authors.forename: R
authors.initials: R
authors.lastname: Oldham
authors.forename: M
authors.initials: M
authors.lastname: Lewis
authors.forename: J
authors.initials: J
authors.lastname: Ogden
authors.forename: S K
authors.initials: SK
authors.lastname: Liao
authors.forename: K
authors.initials: K
authors.lastname: Leung
authors.forename: S
authors.initials: S
authors.lastname: Dupere
authors.forename: R
authors.initials: R
authors.lastname: Birch
authors.forename: B
authors.initials: B
authors.lastname: Avner
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D008937:Mitomycins; D016685:Mitomycin